Clinical Trial: SVV-001 with Nivolumab and Ipilimumab in Patients with Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

U.S., March 22 -- ClinicalTrials.gov registry received information related to the study (NCT06889493) titled 'SVV-001 with Nivolumab and Ipilimumab in Patients with Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)' on March 15.

Brief Summary: The purpose of this study is to determine:

1. The highest dose of the trial intervention that targets neuroendocrine tumors and is tolerated by patients.

2. The highest frequency of dosing of the trial intervention that targets neuroendocrine tumors and is tolerated by patients.

3. The highest dose and frequency of dosing of the trial intervention that targets neuroendocrine tumors with at least the same degree of effectiveness and ...